The North America Benign Prostatic Hyperplasia Therapeutics Market would witness market growth of 3.4% CAGR during the forecast period (2021-2027).
The condition in which the prostate and surrounding tissue enlarge, it is known as benign prostatic hyperplasia (BPH). As a man gets older, his prostate goes through two major growth stages. The first is when the prostate expands in size throughout puberty. The second phase begins around the age of 25 and lasts for the rest of a man's life. When BPH becomes large enough to create issues, it is known as BPH.
Frequent or urgent urination, increased frequency of urination at night (nocturia), trouble commencing urination, weak urine flow or a stream that stops and begins, dribbling at the conclusion of urination, and inability to entirely empty the bladder are all common indications and symptoms of BPH.
According to a report published by the United States Census Bureau in 2018, the number of persons aged 65 and up in the United States is anticipated to rise dramatically between 2016 and 2060. By 2030, one in every five Americans will be 65 or older, accounting for 78.0 million people out of the overall population. This factor the increased geriatric population, this factor would also induce the demand for benign prostatic hyperplasia therapeutics in the region.
The US market dominated the North America Benign Prostatic Hyperplasia Therapeutics Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $2,411.6 million by 2027. The Canada market is expected to witness a CAGR of 6.5% during (2021 - 2027). Additionally, The Mexico market would experience a CAGR of 5.8% during (2021 - 2027).
Based on Therapy, the market is segmented into Mono Drug Therapy and Combination Drug Therapy. Based on Therapeutics Class, the market is segmented into Alpha Blockers, 5- alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Benign Prostatic Hyperplasia Therapeutics Market is Estimated to reach $7.4 Billion by 2027, at a CAGR of 4.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Mono Drug Therapy
- Combination Drug Therapy
By Therapeutics Class
- Alpha Blockers
- 5- alpha Reductase Inhibitors
- Phosphodiesterase-5 Inhibitors
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC (GSK)
- Astellas Pharma, Inc.
- Eli Lilly and Company
- Allergan PLC (AbbVie)
- Merck Group (Merck Sharp & Dohme Corp.)
- Boehringer Ingelheim International GmbH
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Pfizer, Inc.
- Abbott Laboratories
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Benign Prostatic Hyperplasia Therapeutics Market, by Therapy
1.4.2 North America Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class
1.4.3 North America Benign Prostatic Hyperplasia Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy
3.1 North America Mono Drug Therapy Market by Country
3.2 North America Combination Drug Therapy Market by Country
Chapter 4. North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
4.1 North America Alpha Blockers Market by Country
4.2 North America 5- alpha Reductase Inhibitors Market by Country
4.3 North America Phosphodiesterase-5 Inhibitors Market by Country
4.4 North America Others Market by Country
Chapter 5. North America Benign Prostatic Hyperplasia Therapeutics Market by Country
5.1 US Benign Prostatic Hyperplasia Therapeutics Market
5.1.1 US Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.2 US Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2 Canada Benign Prostatic Hyperplasia Therapeutics Market
5.2.1 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.2 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3 Mexico Benign Prostatic Hyperplasia Therapeutics Market
5.3.1 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.2 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market
5.4.1 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.2 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
Chapter 6. Company Profiles
6.1 GlaxoSmithKline PLC (GSK)
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Astellas Pharma, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expense
6.3 Eli Lilly and Company
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expense
6.4 Allergan PLC (AbbVie)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.5 Merck Group (Merck Sharp & Dohme Corp.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Boehringer Ingelheim International Gmbh
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional & Segmental Analysis
6.6.4 Research & Development Expenses
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expenses
6.8 Sanofi S.A.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Abbott Laboratories
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
TABLE 1 North America Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 2 North America Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 3 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 4 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 5 North America Mono Drug Therapy Market by Country, 2017 - 2020, USD Million
TABLE 6 North America Mono Drug Therapy Market by Country, 2021 - 2027, USD Million
TABLE 7 North America Combination Drug Therapy Market by Country, 2017 - 2020, USD Million
TABLE 8 North America Combination Drug Therapy Market by Country, 2021 - 2027, USD Million
TABLE 9 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 10 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 11 North America Alpha Blockers Market by Country, 2017 - 2020, USD Million
TABLE 12 North America Alpha Blockers Market by Country, 2021 - 2027, USD Million
TABLE 13 North America 5- alpha Reductase Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 14 North America 5- alpha Reductase Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 15 North America Phosphodiesterase-5 Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 16 North America Phosphodiesterase-5 Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 17 North America Others Market by Country, 2017 - 2020, USD Million
TABLE 18 North America Others Market by Country, 2021 - 2027, USD Million
TABLE 19 North America Benign Prostatic Hyperplasia Therapeutics Market by Country, 2017 - 2020, USD Million
TABLE 20 North America Benign Prostatic Hyperplasia Therapeutics Market by Country, 2021 - 2027, USD Million
TABLE 21 US Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 22 US Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 23 US Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 24 US Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 25 US Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 26 US Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 27 Canada Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 28 Canada Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 29 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 30 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 31 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 32 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 33 Mexico Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 34 Mexico Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 35 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 36 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 37 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 38 exico Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 39 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market, 2017 - 2020, USD Million
TABLE 40 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market, 2021 - 2027, USD Million
TABLE 41 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2017 - 2020, USD Million
TABLE 42 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy, 2021 - 2027, USD Million
TABLE 43 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2017 - 2020, USD Million
TABLE 44 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class, 2021 - 2027, USD Million
TABLE 45 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 46 key information – Astellas Pharma, Inc.
TABLE 47 Key Information – Eli Lilly and Company
TABLE 48 Key Information – Allergan PLC
TABLE 49 key Information – Merck Group
TABLE 50 Key Information – Boehringer Ingelheim International GmbH
TABLE 51 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 52 Key Information – Sanofi S.A.
TABLE 53 Key Information – Pfizer, Inc.
TABLE 54 Key Information – Abbott Laboratories
List of Figures
FIG 1 Methodology for the research